pharmaceuticals
pharmaceuticals Articles
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine, treatment or test to deal with this coronavirus and here is where their stocks stand now.
Published:
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine, treatment or test to deal with this novel coronavirus. Here's how they fared as the week wound down.
Published:
Amarin has been right in the middle of this recent market sell-off, and while shares have been halved, the stock could be poised for a strong recovery. All the pieces seem to be there.
Published:
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine to deal with this novel coronavirus and where they stand now.
Published:
BioNTech stock jumped on Tuesday and went even higher early on Wednesday. This comes after the company announced a collaboration with the pharmaceutical giant Pfizer.
Published:
Like all developmental drug companies, Bio-Path is betting on the success of its drug candidates. Drugs that are in trials often fail, so investors need to gamble that one or more of its treatments...
Published:
The February 28 short interest data have been compared with the previous figures, and short interest in these top pharmaceutical stocks decreased.
Published:
Shares of Amarin have plunged in recent months. Even more troubling, there appears to no catalyst to drive them higher.
Published:
One of the biggest concerns in the financial markets at this time is that governments and central banks have few obvious policy tools to help keep their economies going if what was seen in China...
Published:
Mylan stock pulled back on Friday after it reported mixed fourth-quarter financial results late Thursday.
Published:
The February 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
The broad markets are getting crushed on Monday on renewed fears of the spread of the coronavirus (Covid-19). But a handful of stocks were acting as a natural hedge to the virus news.
Published:
See why Argus believes that Teva Pharmaceutical has made progress concerning its challenges, which are already baked into the stock price.
Published:
The January 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
CVS Health has faced strong headwinds since last year’s acquisition of health insurer Aetna, but its upcoming earnings report could prove to be a turning point.
Published: